Loading
Loading
Product image is a representation — actual packaging and label may vary.
Nasal Sprays · 7ml
🕐 Pre-order — ships from 31 August 2026
This product is pre-order only right now. Your order will be dispatched once stock arrives on 31 August 2026.
$119
AUD · 1 pack
Flat rate · ships with your order
CJC-1295 + Ipamorelin is a research blend using CJC-1295 without DAC (Mod GRF 1-29) studied in preclinical research for synergistic growth hormone axis regulation. Mod GRF 1-29 has a short half-life (~30 minutes) and stimulates a pulsatile GHRH-receptor signal; Ipamorelin selectively stimulates GH secretion at the pituitary level via the ghrelin receptor. Research has examined their mechanistically complementary, dual-pathway approach for studying synchronised growth hormone pulses, feedback regulation, and endocrine synergism.
Chemical Properties · CJC-1295 No DAC
Chemical Properties · Ipamorelin
Research Use Only — Disclaimer
These consumable supplies are intended solely for use in research and laboratory settings. All items are sterile and individually packaged for professional handling. BAC water is for peptide reconstitution purposes only and is not intended for injection without appropriate professional supervision. Not for human or animal consumption in any form.
CJC-1295 No DAC
Modified GRF(1-29)
CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a 29-amino-acid analog of GHRH(1-44) stabilised by four amino acid substitutions (positions 2, 8, 15, and 27) but without the albumin-binding Drug Affinity Complex. This gives a half-life of ~30 minutes — substantially longer than endogenous GHRH (minutes) but far shorter than CJC-1295 DAC (days), producing discrete GH pulses rather than sustained GH elevation.
Acts on GHRH receptors (GHRHr) on anterior pituitary somatotrophs to stimulate GH synthesis and release, then clears quickly — mimicking a single physiological GHRH pulse. This pulsatile pattern is considered more biomimetic than sustained GH elevation from DAC forms. It is typically administered in combination with a ghrelin mimetic (Ipamorelin, GHRP-2) — the two receptor pathways (cAMP/PKA via GHRHr + IP3/PKC via GHS-R1a) are complementary, producing synergistic GH pulses 2-5× larger than either alone.
Modified GRF 1-29 is the most commonly studied short-acting GHRH analog in combination GH secretagogue protocols. Research encompasses GH-axis stimulation, body composition, recovery, sleep-associated GH release, and age-related GH decline. Its pulsatile GH release profile may better preserve hypothalamic-pituitary feedback compared to sustained-release forms.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
